RecruitingNCT05072483
Natural History Study of CADASIL
Studying Cerebral autosomal dominant arteriopathy-subcortical infarcts-leukoencephalopathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- Principal Investigator
- Elisa A Ferrante Brenlla, Ph.D.National Heart, Lung, and Blood Institute (NHLBI)
- Intervention
- MRI(device)
- Enrollment
- 155 enrolled
- Eligibility
- 18-100 years · All sexes
- Timeline
- 2022 – 2041
Study locations (1)
- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05072483 on ClinicalTrials.govOther trials for Cerebral autosomal dominant arteriopathy-subcortical infarcts-leukoencephalopathy
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE2NCT05755997CERebrolysin In CADASILEver Neuro Pharma GmbH
- RECRUITINGNCT06148051AusCADASIL: An Australian Cohort of CADASILPerminder Sachdev
- RECRUITINGNCT06938100Genotype, Clinical Features and Imaging of Neuroradiological Abnormalities in CADASILFondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
- RECRUITINGNANCT06935578RAre, But Not aLone: a Large Italian Network to Empower the Impervious diaGNostic Pathway of Rare cerEbrovascular Diseases (ALIGNED)Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta